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abstract
Objectives: to determine and document the role of non-tuberculous mycobacteria 
(ntM) in tb-like disease morbidity and demonstrate the confusion they cause in the 
diagnosis of tb in western Kenya. 
Design: a cross-sectional study. 
Setting:  one provincial and nine district hospitals in western Kenya. 
Subjects: tuberculosis suspects. 
Interventions: sputa from 872 tuberculosis suspects underwent microscopy and culture 
on solid and liquid media. The growth was identified using the Hain’s GenoType® 
Mycobacterium cM and genotype® Mycobacterium as kits.  consenting clients were 
screened for hiv infection using trinity biotech uni-goldtM test and positive cases 
were confirmed with the enzyme linked immunosorbent assay. A questionnaire was 
used to obtain demographic data.  
Main outcome measures: Zn smear positivity / negativity; culture positivity or negativity; 
Mycobacterium species isolates (tuberculous or non-tuberculous); hiv status.
Results:  sputa from 39.1% (341/872) of the participants were Zn smear positive, 
of these 53.1% (181/341) were culture positive. only 3.8% (20/531) of the Zn smear 
negatives were culture positive. in total 41.4% (361/872) participants were infected 
with mycobacteria, of which 44.3% (160/361) were culture negative and 55.7% (201/361) 
were culture positive.  the culture positives yielded 92.5% M. tuberculosis complex 
and 7.5% ntM. the overall prevalence of the ntM disease was 1.72% (15/872).  
Conclusion:  a low prevalence of ntM pulmonary disease in western Kenya is reported 
in this study, but some the ntM disease cases could have been misdiagnosed as tb 
cases. 
introduction
The genus Mycobacterium causes more morbidity 
and mortality worldwide than all other bacterial 
infections combined. The most notorious has been 
the M. tuberculosis complex also known as tubercle 
bacillus, followed by the lepra bacillus, M. leprae, 
the aetiological agent of leprosy (1). However, 
the emergence of non-tuberculous mycobacteria 
(NTM) as opportunistic pathogens in HIV/AIDS 
patients is gaining clinical significance. The NTM are 
Mycobacterium species different from those belonging 
to M. tuberculosis complex (2), most of them being 
saprobes (3). However, some are opportunistic 
pathogens, which may cause severe and fatal TB-
like syndromes (4). Skin test data suggest that a high 
proportion of people have been exposed to one or more 
NTM species.  The predominant NTM species may 
vary from country to country and between different 
areas of a country (3, 5, 6).  
 Mycobacterium avium complex (MAC), also 
referred to as M. avium- intracellure (MAI) complex, 
is the most common cause of NTM disease. The 
MAC consists of 28 serovars of two distinct species, 
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M. avium, and M. intracellulare (7), and is responsible 
for progressive and usually fatal disease if untreated, 
especially in immunocompromised patients (1, 8). 
Mycobacterium kansasii is second to MAC in the causation 
of NTM lung disease (1). The American Thoracic Society 
(ATS) (9) reports MAI complex, M. kansasii M. fortuitum 
and M. chelonae as the most common NTM causing 
chronic respiratory disease, with M. kansasii causing 
chronic pulmonary disease similar to reactivation TB. 
Mycobacterium kansasii infection occurs worldwide but 
is most common in the USA and UK (10).  In Kenya, 
M. fortuitum/M. chelonae, M. szulgai, M. kansasii, and M. 
terrae are among the NTM species that have been isolated 
from patients who present with acute radiologically 
confirmed pneumonia (11). 
 Lately however, new NTM species have emerged 
as opportunistic pathogens in HIV/AIDS patients. 
Mycobacterium genasense was first isolated in 1990 from 
a Swiss patient, and is now being reported in other 
European countries, USA, and Australia.  Mycobacterium 
celatum, which seems biochemically indistinguishable 
from M. avium, but shows mycolic acid patterns closely 
related to that of M. xenopi, is also being reported to 
cause disease (12). The other NTM species which have 
been associated with lung disease in HIV/AIDS patients 
include M. malmoense, M. xenopi (13), M. abscessus, 
M. chelonae, M. fortuitum (14), M. asiaticum (15), M. 
haemophilum (16), M. triviale, M. szulgai and M. smegmatis 
(17). Death rates from NTM disease are high even with 
treatment (13). Due the wide spread of HIV in developing 
countries, the role of NTM in mycobacterioses (TB-like 
syndromes) may be underestimated particularly in 
sub-Saharan Africa (4). This study was carried out to 
determine the role of NTM in TB-like disease morbidity 
and demonstrate the confusion they cause in the 
diagnosis of TB in western Kenya.
Materials and Methods
Study Design: A cross-sectional study was conducted 
between September 2007 and September 2009. It was 
carried out to provide a snapshot (one point in time 
measurements) description of the significance of the 
NTM in causing TB-like disease in Western Kenya.  
Study site and population: The study was done at one 
provincial and nine district hospitals in western 
Kenya. These were Busia, Bungoma, Kisumu, Migori, 
Kisii, Narok, Kericho, Uasin Gishu and Lodwar 
district hospitals, and Nakuru Provincial General 
Hospital. Western Kenya includes the expansive 
former Rift Valley, Nyanza and Western Provinces, 
with a cumulative population of about 19.8 million 
people. This constitutes about 52.1% of the Kenyan 
population, according to the Kenya Census of 2009.
Sampling frame and patient characteristics: The 
participants suspected of having pulmonary TB were 
enrolled into the study between September 2007 and 
September 2009 as they sought healthcare services at 
the chest and paediatric clinics. Cases who had prior 
treatment before attending to the clinics were carefully 
screened and those already on anti-TB were excluded. 
Participants were suspected of having TB if they had 
a cough of more than two weeks not responding to 
antibiotic treatment (NLTP, 2003)
Collection of demographic data: A questionnaire was 
used to obtain participant demographic data.  Data 
collected included age, gender, previous anti-TB 
treatment, HIV status and anti-retroviral therapy 
(ART).
Collection of samples: At least two millimetres of three 
sputum specimens (spot, early morning, spot) (18) 
were collected from 872 participants with suspected 
TB under the supervision of trained and competent 
medical staff. The patient were requested to cough 
so that expectoration will come from deep down the 
chest as possible, and spit into sterile 50 ml blue cap 
tubes. The samples were refrigerated at 4oC awaiting 
transportation in cool boxes to the Mycobacteria 
Reference Laboratory, Moi University School of 
Medicine (MRL, MUSOM) weekly for analysis. At the 
MRL, MUSOM, the samples were refrigerated at 4oC 
till processing.  However, the samples were processed 
within seven days of collection in order to minimize 
loss of viability of the mycobacteria. Consenting 695 
participants also underwent phlebotomy for HIV 
testing. The blood was delivered into Vacutainer Brand 
STERILE interior EDTA (K3) tubes and stored at –20oC 
awaiting processing. The samples were transported in 
cool boxes to MRL, MUSOM, Eldoret, and processed 
within two weeks. The safety for research assistants 
and healthcare workers during collection and handling 
of sputum specimens was ensured by observing the 
WHO guidelines (19).
HIV testing:  Screening for HIV infection was done by 
screening serum by the Trinity Biotech Uni-GoldTM test 
(20) and positives confirmed with the enzyme linked 
immunosorbent assay (21).
Microscopic examination of specimens:  Diagnosis 
for mycobacterial disease was done after staining 
specimens with carbol-fuchsin using the ZN method 
(18).
Isolation of mycobacteria and identification of mycobacteria: 
Sputum specimens were processed for isolation of 
mycobacteria following standard protocols (22). The 
mycobacterial isolates were identified as M. tuberculosis 
complex or species of non-tuberculous mycobacteria 
(NTM) using Hain’s GenoType® Mycobacterium CM 
and GenoType® Mycobacterium AS Molecular Genetic 
Assays, following manufacturer’s instructions (23). 
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The suspects with ZN smear positive but culture 
negative sputa were treated as smear negative 
pulmonary TB cases.
Data analysis: Data were entered in MS Excel 8.0 and 
analysed using Epi Info version 3.5.1 to calculate 
proportions. Descriptive statistics were used to 
summarise data.  
Ethical issues: The proposal for this study was approved 
by ITROMID / KEMRI’s Scientific Steering Committee 
(SSC) and Ethical Review Committee (ERC) [SSC No. 
837] and by Moi University School of Medicine (MU-
SOM) / Moi Teaching and Referral Hospital (MTRH) 
Institutional Research and Ethics Committee (IREC) 
[FAN No.00092]. The study was conducted in accordance 
with the Declaration of Helsinki (24). Results on TB, NTM 
disease and HIV infection were availed to respective 
healthcare givers for appropriate patient care. The HIV 
positive cases were referred for post-test counselling 
and enrolment to HIV/AIDS Programme.
results
Study participants:  A total of 872 TB suspects were 
enrolled into the study, 54.9% (477) males and 45.1% 
(393) females. Their median age was 32 years.  The 
majority (33.1%) were in the 25-34 age-group, followed 
by those in the 35-44 (21.8%) and 15-24 (18.7%) age 
brackets respectively.  Paediatric cases (0-14 age-
group) were the lowest with 4.6%, with children below 
five years accounting for only 0.6% (Table 1).
Smear microscopy and culture:  Sputum specimens 
from 39.1% (341/872) cases were ZN smear positive, 
of which 53.1% (181/341) were culture positive.  Of 
the ZN smear negative, 3.8% (20/531) were culture 
positive. Hence, of the 41.4% (361/872) cases with 
mycobacterial disease, 44.3% (160/361) were culture 
negative and 55.7% (201/361) were culture positive. 
Among the culture positives, 92.5% of the isolates 
were M. tuberculosis complex and 7.5% were NTM. 
The 42.6% (160/341) cases that were ZN smear 
positive but culture negative were regarded and 
treated as TB.  No cultures yielded tuberculous and 
non-tuberculous mycobacteria co-infection.  Five of 
the NTM isolates were identified as M. intracellulare 
(3 isolates), and M. fortuitum and M. peregrinum one 
isolate each.  The remaining ten NMT isolates could 
not be identified to species level.
 Of the 15 NTM disease cases, ten were males and 
five were females.  The majority (40%) of the NTM 
infection cases were in the 25-34 year age-group, 
followed by the 15-24 year age-group with 20% (Table 
2).  Four of the NTM disease cases (three males and 
one female) had been previously treated for TB. Six 
(40%) of cases were co-infected with HIV, five (33.3%) 
were HIV negative, and four (26.7%) were of unknown 
HIV status. Three of the NTM-HIV co-infection cases 
were on antiretroviral therapy (ART).
table 2 
Gender-age distribution of NTM disease cases 
Age-group N (%) Males (%) Females (%)
0-14 1(6.7) 0 1(6.7)
15-24 3(20.0) 2(13.3) 1(6.7)
25-34 6(40.0) 4(26.7) 2(13.3)
35-44 2(13.3) 2(13.3) 0
45-54 1(6.7) 0 1(6.7)
55-64 1(6.7) 1(6.7) 0
> 64 1(6.7) 1(6.7) 0
Total 15(100) 10(66.7) 5(33.3)
table 1
Distribution of study participants by gender-age 
Age-group N (%) Males (%) Females (%)
0-14 39(4.5) 22(2.5) 18(2.1)
15-24 163(18.7) 80(9.2) 83(9.5)
25-34 288(33.1) 162(18.6) 126(14.4)
35-44 190(21.8) 108(12.4) 82(9.4)
45-54 89(10.2) 108(12.4) 36(4.1)
55-64 54(6.2) 29(3.3) 25(2.9)
> 64 48(5.5) 25(2.9) 23(2.6)
Total 872(100) 479(54.9) 393(45.1)
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discussion
The NTM disease is being associated with HIV/
AIDS and encountered with increasing frequency 
in non-aids patients (9). However, most of the data 
reporting high rates of NTM disease come from 
developed countries (4). In Africa, the contribution 
of NTM to the clinical problem of TB has so far only 
been examined at a very low scale. In South Africa 
for instance, two studies have reported prevalence 
rates of NTM colonisation / infection of 1, 400 and 
6,700 per 100,000 respectively (25). In Zambia, Buijtels 
[4] has reported NTM colonisation rate of 14/154 
(9%) in the patient population with a disease rate of 
3/154 (2%), and a colonisation rate of 61/383 (16%). 
In present study, 7.5% (15/201) of the mycobacterial 
disease cases were NTM TB-like syndromes, giving an 
overall prevalence of 1.72% (15/872). However, since 
NTM diseases are frequent in HIV infected patients 
in low income countries (26), some of the 160 ZN 
smear positive but culture negative cases treated as 
TB in the current study could be NTM disease cases. 
This could imply underestimations of the prevalence 
rates of non-tuberculous mycobacterioses in high HIV 
prevalence countries.   
 While tremendous progress has been made in 
tuberculous and non-tuberculous mycobacterioses 
diagnostics in developed countries, techniques 
for the diagnosis of these diseases have remained 
relatively unchanged (invariably based on ZN 
smear microscopy) in Africa and other resource-
poor settings, albeit supplemented by chest X-ray in 
some settings.  The level of sophistication and cost 
associated with the new and more sensitive techniques 
have made their general applicability unfeasible 
in developing countries (4), where the basis for TB 
diagnosis has continued to be ZN smear microscopy of 
specimens to visualise acid-fast bacteria (AFB), which 
may capture 50-69% of the cases when carried out 
by experienced technicians. However, in most low-
income countries, much lower rates of case detection 
are achieved due to poor quality microscopes, heavy 
workload, and shortage of trained staff. Moreover, 
ZN smear microscopy is usually negative in less 
advanced disease especially among HIV/AIDS co-
infected patients and extra-pulmonary TB cases.  The 
proportion of cases detected by microscopy in some 
low-income countries is often as low as 20-30% of all 
cases (4, 27).  
 The diagnosis of smear-negative pulmonary TB 
(PTB) may even be more complicated when reliance 
is solely placed on clinical and radiological features, 
which may not distinguish NTM TB-like respiratory 
syndrome from PTB. However, to guide the diagnosis 
of the NTM pulmonary mycobacterioses, the 
bacteriological diagnostic criteria established by the 
American Thoracic Society (ATS) (9) can provide 
support; a single NTM culture from bronchial 
washing fluid or two positive sputum cultures, in 
a symptomatic patient with nodular or cavitary 
opacities in the chest radiograph (28). In the present 
study, however, NTM disease was diagnosed based 
on at least two positive cultures from two separate 
expectorated sputa from symptomatic patients with 
chest pain, with or without ZN smear positivity. 
However, lack of patient chest X-ray data to augment 
clinical, microscopic and culture findings could be a 
significant limitation of the current study. 
 The highly discouraging finding in the current 
study is the high rate (42.6%) of ZN smear positive 
but culture negative cases treated as TB observed in 
the present study. Not all acid fast bacilli represent 
mycobacteria, let alone M. tuberculosis complex. 
The NTM (26) and some other bacterial species 
including Nocardia and Rhodococcus species which 
are widely spread in the environment yield positive 
results in ZN smear detection of acid-fast bacilli 
(AFB) and may present with similar radiological 
features (29). Moreover, a number of NTM including 
M. haemophilum, M. genavense, M. avium subsp. 
paratuberculosis (formerly M. paratuberculosis), and 
M. ulcerans are fastidious and require special nutrient 
supplementation for optimal recovery on cultures. 
For instance, M. haemophilum grows only on media 
supplemented with iron-containing compounds 
such as ferric ammonium citrate, hemin, or 
haemoglobin, while M. genavense and M. avium subsp. 
paratuberculosis require mycobactin J incorporated into 
the medium. Similarly, M. ulcerans may be optimally 
recovered with egg yolk supplementation (9). Worthy 
noting also is that a significant proportion of patients, 
especially HIV positive may give negative ZN smear 
results.
 From the foregoing and the results of current 
study, it is evident that ZN microscopy as a diagnostic 
tool for TB is imprecise and causes a significant over-
diagnosis of TB among HIV/AIDS patients. Some 
of NTM disease cases could be misdiagnosed as TB 
and put on anti-TB chemotherapy, even though the 
treatment of NTM disease is generally not directly 
analogous to TB treatment (9,28). Multi-drug 
regimes are used for NTM TB-like disease treatment, 
the cornerstone agents being a newer macrolide 
(azithromycin, clarithromycin) (28), ethambutol, and 
rifamycin, and require prolonged durations of therapy 
aimed to facilitate clearance of the mycobacteria 
and minimise the emergence of drug resistance (9, 
28). However, cure of NTM disease is not the goal 
of therapy in all patients. Palliation of symptoms 
or minimisation of disease progression may be 
the desired result for some patients. Symptomatic, 
radiographic, and microbiologic improvement 
(conversion of sputum cultures) may be the desired 
treatment outcome (9). Patients frequently show 
clinical improvements within four to six months of 
beginning therapy, with negative sputum cultures 
302 East african MEdical Journal September 2011 
typically occurring within six to twelve months 
on multiple-drug regimens. The requirement that 
treatment be continued for up to 12 months of 
documented negative sputum cultures translates to 
treatment duration of 18 to 24 months, but it may 
be longer for some patients. However, treatment 
failure is not uncommon (no clinical improvements 
after six months or positive sputum culture after 
12 months of appropriate therapy), which may be 
related to treatment non-compliance or intolerance, 
anatomic defects (cavitation or bronchiectasis), or 
drug resistance (especially to macrolides). Relapses 
and re-infections are also common and may not be 
related to drug susceptibility (30). Additionally, the 
treatment regimens are expensive, and often poorly 
tolerated because of frequent side effects (toxicity), 
with patients often describing the treatment to be 
worse than the disease itself (9).  
 
In conclusion, the prevalence of NTM disease 
in Western Kenya may be considered low, but a 
comprehensive national survey on NTM TB-like 
morbidity is necessary. Some of the NTM pulmonary 
disease cases could have been misdiagnosed as TB, 
considering that a high number of ZN smear positive 
but culture negative cases were treated as TB cases.
 
acKnowledgeMents
To the Medical Officers of Health, Medical 
Superintendents, District Leprosy and Tuberculosis 
Coordinators, Laboratory staff and clinical and 
nursing staff at Narok, Kericho, Lodwar, Uasin 
Gishu, Bungoma, Busia, Kisumu, Migori, Kisii 
District Hospitals and Nakuru Provincial General 
hospital who greatly assisted us with specimen and 
data collection for this study.  We are also indebted 
to the Laboratory Technicians at the Mycobacteria 
Reference Laboratory, MUSOM who assisted with 
laboratory work.  We wish to thank the Global Fund 
TB Round 5 Project for funding this study through 
the Government of Kenya.  Special thanks go to Prof. 
Dr. Dick van Soolingen of the National Institute for 
Public Health and the Environment, the Netherlands, 
who offered unlimited technical advice and assisted 
in the acquisition of the BACTEC MGIT 960 without 
which this study could not be done.  
references
1.  Iseman, M. D. Nontuberculous mycobacteria. Medical 
Scientific Update. 1998; 15: 1-4.
2.   Dawson, D. J.  Mycobacterial terminology.  J. Clin. 
Microbiol. 2000; 38: 3913.
3.  Falkinham, J. O. Epidemiology of infection caused by 
non-tuberculous mycobacteria. Clin. Microbiol. Rev. 
1996; 9: 177-215.
4.   Buijtels, P. C. A. M. Clinical relevance of non-tuberculous 
mycobacteria in Zambia.  PhD thesis, 2007.
5.   Wolinsky, E. Epidemiology of non-tuberculous 
mycobacterial infections.  Rev. Infect. Dis. 1981; 3: 
990.
6.   Wolinsky, E.  Mycobacterial diseases other than 
tuberculosis.  Clin. Infect. Dis. 1992; 15: 1.
7.   Thorel, M. F., Krichevsky, M., and Levy-Frebault, 
V.  Numerical taxonomy of mycobacteria, emended 
description of Mycobacterium avium, and description of 
Mycobacterium avium subsp. avium nov, Mycobacterium 
avium subsp. paratuberculosis nov, Mycobacterium avium 
subsp. silvaticum subsp. nov. Int. J. Syst. Bacteriol 1990; 
40: 254-260.
8.   Richter, E., Wessling, J., Lugering, N. et al. 
Mycobacterium avium subsp. paratuberculosis 
infection in a patient with HIV, Germany.  Emerg. 
Infect. Dis. 2002; 8: 729-31.
9.   American Thoracic Society (ATS). An Official 
ATS/IDSA Statement: Diagnosis, Treatment, and 
Prevention of Nontuberculous Mycobacterial 
Diseases. 2007
10.  Johnson, J. L. and Ellner, J. J.  Tuberculosis and Atypical 
Mycobacterial Infections.  In: Guerrrant, R. L., Walker, 
D. H. and Weller, P. F., editors. Tropical Infectious 
Diseases: Principles, Pathogens & Practice, Vol. 1. 
Philadelphia: Churchill Livingstone.  1999: 443-73.
11.   Scott, J. A., Hall, A. J., Muyodi, C. et al.  Aetiology, 
outcome, and risk factors for mortality among adults 
with acute pneumonia in Kenya.  Lancet. 2000; 355: 
1225-1230.
12.   Garcia-Garrote, F., Ruiz-Serrano, J. M., Cosin, J., et 
al.  Mycobacterium celatum as a cause of disseminated 
infection in AIDS patients: a case report and literature 
review Clin Microbial Infect 1997; 3: 582-584.   
13.  Pozniak, A.  Treatment of the non-tuberculous 
mycobacterial disease (excluding HIV patients).  Int. 
J. Tuberc. Lung. Dis. 1997; 1 Supl 1: S13.
14.   von Reyn, C. F.  Epidemiology of infections due to 
Mycobacterium avium complex.  Int. J. Tuberc. Lung 
Dis. 1997; 1 Supl 1: S12.
15.   Bonard, D., Aka, K., Zahibo, J., et al. HIV-associated 
mycobacteria in West Africa.  Int. J. Tuberc. Lung Dis. 
1999; 3: 546.
16.   Sampaio, J. L. M., Alves, V. A. F., de Magalhaes, V. 
D. et al.  Mycobacterium haemophilum: emerging or 
under diagnosed in Brazil?  Emerg. Infect. Dis. 2002; 
8: 1359.
17.   Saidi, G. K., Roayai, M., Zarifi, A. Z., et al. Isolation of 
environmental mycobacteria from patients suspected 
of tuberculosis (TB) in Ahvaz, South West of Iran. Int 
J. Tuberc. Lung Dis. 1997; 1 Supl 1: S147.
18.   Find.  MGITTM Procedure Manual for BACTEC TM 
MGIT 960TM TB System. 2006
19.   World Health Organization (WHO).  Guidelines for 
the prevention of tuberculosis in healthcare facilities 
in resource-limited settings. WHO, Geneva. 1999.
20.   Trinity Biotech. Uni-GoldTM HIV insert. 2008.
21.   ABBOT murex, Murex Biotech Limited, UK. Murex 
HIV Ag/Ab Combination Insert. 2007
22.   Becton Dickinson (BD). BBL MGIT Package inserts. 
2008.
23.   Hain lifescience, GmbH, Nehren, German. Package 
inserts. 2008
24.  World Medical Organization. Declaration of Helsinki. 
British Med. J. 1996; 313: 1448-1449. 
September 2011 East african MEdical Journal   303
25.   Faurie, P. B., Gatner, E. M., Glatthaar, E., et al.  Follow-
up tuberculosis prevalence survey of Transkei. 
Tubercle.  1980; 61: 71-79.  
26.  Buijtels, P. C. A. M., van der Sande, M. A. B., de Graaff, 
C. S. et al.  Nontuberculous mycobacteria, Zambia. 
Emerg. Infect. Dis. 2009; 15: 242-249.
27.   Corbett, E. L., Watt, C. J., Walker, N., et al.  The 
growing burden of tuberculosis:  global trends and 
interactions with HIV epidemic. Arch. Intern. Med 
2003; 163: 1009-1021.
28.   Griffith, D.E., Aksamit, T., Brown-Elliot, B. A., et al. An 
official ATS/IDSA statement: diagnosis, treatment, and 
prevention of non-tuberculous mycobacterial diseases. 
Am. J. Respir. Crit. Care Med. 2007; 175: 367-416.
29.   Olson, E. S., Simpson, A. J., Norton, A. J., et al.  Not 
everything acid fast is Mycobacterium tuberculosis: 
a case report. J. Clin. Pathol. 1998; 51: 535-536.
20.   Lettieri, C. J.  Nontuberculous Mycobacteria: Update on 
Diagnosis and Treatment. From Medscape Pulmonary 
Medicine, Medscape Education. April 1, 2011.
